Dr Mohammad (Mo) Haskali graduated with a PhD in radiopharmaceutical sciences from the University of Melbourne and then joined Cyclotek Pty. Ltd. (2013 – 2014), a company that generates radioactive drugs for the diagnosis and treatment of diseases, including cancer. He then furthered his academic and clinical expertise in the development of radioactive drugs for PET imaging at the National Institute of Mental Health (NIMH) in the USA (2014 – 2016). He then joined the Peter MacCallum Cancer Centre (PMCC) as a senior radiopharmaceutical scientist (2016 – 2023). He currently serves as PMCC’s inaugural Chief Radiopharmaceutical Scientist. He currently leads the clinical provision of radiopharmaceuticals, drugs capable of detecting and targeting tumours for destruction and also leads a research program developing new radioactive drugs for clinical use.

 

Dr Haskali is a certified radiopharmaceutical scientist by the Australasian College of Physical Scientists and Engineers in Medicine. He currently sits on the professional standards board (PSB) of the ACSPEM as the national representative of radiopharmaceutical sciences in Australia (2019 – 2023).

 

Dr Haskali’s research group is involved with all aspects of radiopharmaceutical sciences including i) developing new methods for radiolabelling bioactive molecules, ii) design and synthesis of new radiotracers/theranostics for PET imaging and radionuclide therapy, and iii) clinical provision of radiopharmaceuticals.

 

Dr Haskali has a strong personal interest in all chemical aspects of the discovery, development and evaluation of novel radioactive probes for molecular imaging with PET and targeted radionuclide therapy.